1
|
Domingues A, Jolibois J, Marquet de Rougé P, Nivet-Antoine V. The Emerging Role of TXNIP in Ischemic and Cardiovascular Diseases; A Novel Marker and Therapeutic Target. Int J Mol Sci 2021; 22:ijms22041693. [PMID: 33567593 PMCID: PMC7914816 DOI: 10.3390/ijms22041693] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 02/03/2021] [Accepted: 02/04/2021] [Indexed: 12/17/2022] Open
Abstract
Thioredoxin interacting protein (TXNIP) is a metabolism- oxidative- and inflammation-related marker induced in cardiovascular diseases and is believed to represent a possible link between metabolism and cellular redox status. TXNIP is a potential biomarker in cardiovascular and ischemic diseases but also a novel identified target for preventive and curative medicine. The goal of this review is to focus on the novelties concerning TXNIP. After an overview in TXNIP involvement in oxidative stress, inflammation and metabolism, the remainder of this review presents the clues used to define TXNIP as a new marker at the genetic, blood, or ischemic site level in the context of cardiovascular and ischemic diseases.
Collapse
Affiliation(s)
- Alison Domingues
- INSERM 1140, Innovative Therapies in Haemostasis, Faculty of Pharmacy, Université de Paris, 75006 Paris, France; (A.D.); (J.J.); (P.M.d.R.)
| | - Julia Jolibois
- INSERM 1140, Innovative Therapies in Haemostasis, Faculty of Pharmacy, Université de Paris, 75006 Paris, France; (A.D.); (J.J.); (P.M.d.R.)
| | - Perrine Marquet de Rougé
- INSERM 1140, Innovative Therapies in Haemostasis, Faculty of Pharmacy, Université de Paris, 75006 Paris, France; (A.D.); (J.J.); (P.M.d.R.)
| | - Valérie Nivet-Antoine
- INSERM 1140, Innovative Therapies in Haemostasis, Faculty of Pharmacy, Université de Paris, 75006 Paris, France; (A.D.); (J.J.); (P.M.d.R.)
- Clinical Biochemistry Department, Assistance Publique des Hôpitaux de Paris, Necker Hospital, 75015 Paris, France
- Correspondence:
| |
Collapse
|
2
|
Ajaero CN, Chong CR, Procter NEK, Liu S, Chirkov YY, Heresztyn T, Chan WPA, Arstall MA, McGavigan AD, Frenneaux MP, Horowitz JD. Does cardiac resynchronization therapy restore peripheral circulatory homeostasis? ESC Heart Fail 2017; 5:129-138. [PMID: 29030923 PMCID: PMC5793973 DOI: 10.1002/ehf2.12211] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2017] [Revised: 07/24/2017] [Accepted: 08/09/2017] [Indexed: 11/17/2022] Open
Abstract
Aims To evaluate whether peripheral circulatory ‘remodelling’ as measured by changes in vascular compliance and in markers of nitric oxide signalling contributes to patient response to cardiac resynchronization therapy (CRT). Methods and results Effects of CRT were evaluated in 33 patients pre‐procedure and 6 months post‐procedure. Peak oxygen consumption, 6 min walk distance, New York Heart Association class, and quality of life score were evaluated. Augmentation index and its interactions with nitric oxide (NO) were evaluated by applanation tonometry. Platelet NO responsiveness and content of thioredoxin‐interacting protein were assessed. Plasma concentrations of N‐terminal proBNP, asymmetric and symmetric dimethylarginine (SDMA), high sensitivity C‐reactive protein, catecholamines, and matrix metalloproteinases‐2 and ‐9 were assessed. Despite significant improvement in 6 min walk distance (P = 0.005), New York Heart Association class (P < 0.001), quality of life (P = 0.001), and all echocardiographic parameters post‐CRT, there were no significant changes in augmentation index measurements, thioredoxin‐interacting protein content, and platelet NO response. Significant falls in N‐terminal proBNP (P = 0.008) and SDMA (P = 0.013; independent of renal function) occurred. Falls in SDMA predicted reduction in high‐sensitivity C‐reactive protein (P = 0.04) and increases in peak oxygen consumption (P = 0.04). There were no correlations between changes in echocardiographic parameters and those in vascular function. Conclusions These data suggest that the beneficial effects of CRT over 6 months are independent of any change in peripheral NO‐related signalling. However, there is evidence that suppression of inflammation occurs, and its magnitude predicts extent of clinical improvement.
Collapse
Affiliation(s)
- Chukwudiebube N Ajaero
- The Queen Elizabeth Hospital, Adelaide, Australia.,The University of Adelaide, Adelaide, Australia.,Flinders Medical Centre, Adelaide, Australia
| | - Cher-Rin Chong
- Cardiac Metabolism Research Group, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.,School of Medicine, The University of Adelaide, Adelaide, Australia
| | - Nathan E K Procter
- Bob Champion Research and Education Building, University of East Anglia, Norwich, UK
| | - Saifei Liu
- Basil Hetzel Institute, Adelaide, Australia
| | - Yuliy Y Chirkov
- The University of Adelaide, Adelaide, Australia.,Basil Hetzel Institute, Adelaide, Australia
| | | | - Wai Ping Alicia Chan
- The Queen Elizabeth Hospital, Adelaide, Australia.,The University of Adelaide, Adelaide, Australia.,The Lyell McEwin Hospital, Adelaide, Australia
| | - Margaret A Arstall
- The University of Adelaide, Adelaide, Australia.,Northern Adelaide Local Health Network, Adelaide, Australia
| | - Andrew D McGavigan
- Flinders Medical Centre, Adelaide, Australia.,Flinders University, Adelaide, Australia
| | - Michael P Frenneaux
- Bob Champion Research and Education Building, University of East Anglia, Norwich, UK
| | - John D Horowitz
- The Queen Elizabeth Hospital, Adelaide, Australia.,The University of Adelaide, Adelaide, Australia
| |
Collapse
|